Schisandra for Health & Longevity - Quick Reference Sheet

Schisandra for Health & Longevity

Created on 07/31/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A traditional berry studied as a stress-resilience and healthy-aging supplement. The most credible human benefits are modest: better muscle strength when paired with light exercise, some relief of menopausal symptoms, and small improvements in blood sugar and cholesterol. Liver-protection evidence is strong in animals but unproven in people. Its main caution: it can change blood levels of some prescription drugs. (Full Review)

Protocol

Dose
500–2,000 mg/day
Standardized berry extract; 1,000 mg/day used in trials
Timing
Morning, with food
Early afternoon acceptable; berry can be mildly stimulating
Frequency
Once daily
Split into two doses at ≥1,500 mg/day
Time to effect
Muscle strength
8–12 weeks
Measured in trials, paired with light exercise
Menopausal symptoms
12 weeks
Symptom scores improved over trial
GI tolerance
Within days
Digestive tolerance apparent early

Benefits

Contraindications
  • Pregnancy
  • Immunosuppressants (tacrolimus, cyclosporine, sirolimus)
  • Active peptic ulcer or severe GERD
  • Epilepsy or raised intracranial pressure
Key Interactions
  • CYP3A4 substrates (statins, amlodipine, nifedipine, midazolam)
  • Warfarin
  • P-glycoprotein substrates (digoxin, some oral anticoagulants)
  • CYP3A-modulating botanicals (St. John's wort, grapefruit, Rhodiola)
  • Additive glucose-lowering agents (berberine, antidiabetic drugs)

Risk & Side Effects

  • High:
  • Medium: Gastrointestinal upset; herb–drug interactions
  • Low: Allergic & skin reactions; contraindication in pregnancy
  • Speculative: Central nervous system overstimulation; aggravation of reflux, peptic ulcer, or seizure disorders

Monitoring

Marker Target Why
ALT ~10–26 U/L Primary marker of liver-cell stress
AST ~10–26 U/L Complements ALT to gauge liver injury
GGT <20–25 U/L Sensitive marker of liver/biliary stress and oxidative load
Fasting glucose 75–90 mg/dL Tracks the metabolic-support signal seen in trials
HbA1c <5.4% Reflects 3-month average glucose for metabolic goals
Tacrolimus/cyclosporine trough Per transplant target Detects the key drug-interaction risk in immunosuppressed users

Cadence: Re-check relevant labs at 8–12 weeks, then every 6–12 months during continued use; anyone co-administering a CYP3A-metabolized drug needs drug-level checks within 1–2 weeks of any change.

Qualitative Assessment

  • Perceived physical stamina and recovery from exertion
  • Muscle strength or ease with daily physical tasks
  • Menopausal symptom burden — hot flushes, sweating, palpitations
  • Energy, mental clarity, and resilience to stress
  • Sleep quality
  • Gastrointestinal comfort